ArticleFrontiers in endocrinology2025
Early identification of sarcopenia in patients with diabetes mellitus combined with osteoporosis: development and validation of a gender-specific nomogram.
Article in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- β-Caryophyllene confers protection against type 2 diabetic osteoporosis by blocking ferroptosis via the AMPK/Nrf2 pathway.Journal of pharmaceutical analysis · 2026Article
- A nomogram integrating machine learning with clinical predictors for osteosarcopenia risk prediction in type 2 diabetes mellitus.Frontiers in endocrinology · 2026Article
- Association between age-related macular degeneration and osteoporosis in US.Scientific reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: The aim of this study was to develop a predictive model to screen for sarcopenia in patients with type 2 diabetes mellitus (T2DM) combined with osteoporosis, with a view to identifying and intervening early in those at high risk of falls and fractures, thereby reducing the risk of disability and death in the elderly. Methods: Clinical data collection, physical performance evaluations, and dual-energy X-ray absorptiometry were performed on 847 patients with T2DM combined with osteoporosis. Risk factors for sarcopenia were identified using the least absolute shrinkage and selection operator method. Furthermore, a sex-specific nomogram was constructed based on these indicators to predict the occurrence of sarcopenia, and the predictive efficacy and clinical value of the model were evaluated by receiver operating characteristic curve and decision curve analysis. Results: The prevalence of sarcopenia in patients with T2DM combined with osteoporosis was 33.88%, with men having a significantly higher prevalence than women. Among male patients, body mass index, 25-hydroxyvitamin D, and calcium levels were associated with a decreased risk of sarcopenia, whereas age and weight-adjusted waist index were associated with an increased risk. In female patients, body mass index and creatine kinase were associated with a decreased risk of sarcopenia, while age, weight-adjusted waist index, and low-density lipoprotein cholesterol were associated with an increased risk. The area under the receiver operating characteristic curve of the nomogram was 91.2% in males and 84.5% in females, showing high predictive accuracy. Conclusions: In this study, gender-specific nomograms were successfully established, which provided an effective tool for early screening of sarcopenia in patients with T2DM combined with osteoporosis. These models help healthcare professionals identify individuals at high risk of falls and fractures, facilitating timely preventive measures and reducing the burden on the social healthcare system.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.